OBJECTIVE:Sleep disturbances appear as a comorbid condition in children with attention-deficit/hyperactivity disorder. The aim of this study was to investigate the relationship of activity levels during sleep and therapeutic response to methylphenidate (MPH). METHOD: Nightly sleep actigraphic recordings during a double-blind, placebo-controlled, crossover clinical study (1-week of 0.5 mg/kg MPH; 1-week of placebo) were obtained on 44 children, 6 to 12 years old, diagnosed with attention-deficit/hyperactivity disorder (DSM-IV). RESULTS: Significant (p <.005) differences between the conditions were found in several software-computed parameters: sleep onset latency (MPH, 39.3 minutes; placebo, 28.2 minutes), sleep efficiency (MPH, 78.0%; placebo, 80.4%), total sleep time (MPH, 7 hours; 57 minutes; placebo, 8 hours, 16 minutes). No significant differences on any of these measures were found among the 26 subjects who showed a moderate or large global improvement on MPH over placebo compared with 18 subjects who showed mild or no clinical improvement. CONCLUSIONS: MPH, given twice daily, induces a slight but significant sleep disturbance. Motor activity levels during sleep did not differentiate children who responded to MPH from those who did not respond. This suggests that responders to MPH treatment do not experience greater sleep disturbances than nonresponders, at least at the dose studied.
RCT Entities:
OBJECTIVE:Sleep disturbances appear as a comorbid condition in children with attention-deficit/hyperactivity disorder. The aim of this study was to investigate the relationship of activity levels during sleep and therapeutic response to methylphenidate (MPH). METHOD: Nightly sleep actigraphic recordings during a double-blind, placebo-controlled, crossover clinical study (1-week of 0.5 mg/kg MPH; 1-week of placebo) were obtained on 44 children, 6 to 12 years old, diagnosed with attention-deficit/hyperactivity disorder (DSM-IV). RESULTS: Significant (p <.005) differences between the conditions were found in several software-computed parameters: sleep onset latency (MPH, 39.3 minutes; placebo, 28.2 minutes), sleep efficiency (MPH, 78.0%; placebo, 80.4%), total sleep time (MPH, 7 hours; 57 minutes; placebo, 8 hours, 16 minutes). No significant differences on any of these measures were found among the 26 subjects who showed a moderate or large global improvement on MPH over placebo compared with 18 subjects who showed mild or no clinical improvement. CONCLUSIONS:MPH, given twice daily, induces a slight but significant sleep disturbance. Motor activity levels during sleep did not differentiate children who responded to MPH from those who did not respond. This suggests that responders to MPH treatment do not experience greater sleep disturbances than nonresponders, at least at the dose studied.
Authors: Michael C Antle; Hester C van Diepen; Tom Deboer; Pardis Pedram; Rob Rodrigues Pereira; Johanna H Meijer Journal: Neuropsychopharmacology Date: 2012-07-04 Impact factor: 7.853
Authors: Sang Heon Lee; Wan Seok Seo; Hyung Mo Sung; Tae Young Choi; So Yeun Kim; So-Jeong Choi; Bon Hoon Koo; Jong Hun Lee Journal: Psychiatry Investig Date: 2012-11-12 Impact factor: 2.505
Authors: Emily Carias; Dennis Fricke; Abisha Vijayashanthar; Lauren Smith; Rathini Somanesan; Connor Martin; Leanna Kalinowski; Daniel Popoola; Michael Hadjiargyrou; David E Komatsu; Panayotis K Thanos Journal: Behav Brain Res Date: 2018-08-24 Impact factor: 3.332
Authors: Panayotis K Thanos; Lisa S Robison; Jessica Steier; Yu Fen Hwang; Thomas Cooper; James M Swanson; David E Komatsu; Michael Hadjiargyrou; Nora D Volkow Journal: Pharmacol Biochem Behav Date: 2015-01-29 Impact factor: 3.533
Authors: Yona K Cloonan; Yemiserach Kifle; Scott Davis; Matthew L Speltz; Martha M Werler; Jacqueline R Starr Journal: Pediatrics Date: 2009-07-27 Impact factor: 7.124
Authors: Jorge Mendoza; Hester C van Diepen; Rob Rodrigues Pereira; Johanna H Meijer Journal: Psychopharmacology (Berl) Date: 2018-05-18 Impact factor: 4.530